Peptide Combination Profile
Ultima IPA+CJC 5mg+5mg is a dual-peptide formulation combining ipamorelin and CJC-1295 (without DAC) manufactured by Ultima Pharmaceuticals. This research-grade combination provides researchers with two complementary growth hormone secretagogue peptides in a single preparation. Ipamorelin functions as a selective ghrelin receptor agonist with pentapeptide structure, whilst CJC-1295 represents a growth hormone releasing hormone analogue with modified amino acid positions. The formulation enables comprehensive investigation of synergistic peptide interactions in controlled laboratory environments. Researchers studying growth hormone axis modulation at Stroid UK Shop can examine these compounds’ distinct mechanisms within a unified experimental framework.
Laboratory Research Applications
This peptide combination offers extensive research opportunities for investigating growth hormone secretagogue pathways. Ipamorelin demonstrates selective ghrelin receptor binding without significantly affecting cortisol or prolactin levels in preclinical models, making it valuable for studying targeted GH stimulation. CJC-1295 provides sustained GHRH receptor activation through its modified structure featuring amino acid substitutions at positions 2, 8, 15, and 27. Researchers examining CJC-1295 peptide combinations can investigate temporal release patterns and receptor affinity profiles. The dual formulation enables studies of peptide synergy, comparative bioavailability, and differential receptor targeting. Advanced peptide research facilities studying SARMs and growth factors benefit from this comprehensive approach to growth hormone axis investigation. The combination format supports comparative studies between individual peptide components and their combined effects in various research models.
Technical Specifications
| Parameter | Value |
|---|---|
| Manufacturer | Ultima Pharmaceuticals |
| Peptide 1 | Ipamorelin 5mg |
| Peptide 2 | CJC-1295 (without DAC) 5mg |
| Total Content | 10mg dual peptide |
| Form | Lyophilised powder |
| CAS Numbers | Ipamorelin: 170851-70-4, CJC-1295: 863288-34-0 |
| Storage | -20°C lyophilised, 2-8°C reconstituted |
| Stability | 30 days post-reconstitution |
Researchers investigating peptides require precise molecular weights for accurate preparation: ipamorelin presents 711.85 g/mol whilst CJC-1295 demonstrates 3367.97 g/mol. Both peptides maintain stability under appropriate storage conditions with lyophilised powder requiring ultra-low temperatures for long-term preservation.
Research Compliance Statement
Ultima IPA+CJC 5mg+5mg is manufactured exclusively for in-vitro laboratory research applications and is not intended for human consumption, clinical use, or therapeutic application. This dual-peptide formulation is supplied to qualified research institutions and laboratories for scientific investigation purposes only. Researchers must maintain appropriate laboratory protocols, safety procedures, and regulatory compliance when handling these research peptides. The product requires proper storage conditions and reconstitution procedures to maintain molecular integrity throughout experimental protocols.
